Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXiaoliang WangGMGregory A. Maglinte

Discussion

Loading...

Member takes

Overview

Real-world outcomes show ZANU lowers treatment risk and trends toward improved survival compared to ACA in CLL.

Key Points

  • The aim was to evaluate treatment patterns and outcomes of BTK inhibitors in CLL patients with varying characteristics.
  • Retrospective observational study of patients treated with zanubrutinib or acalabrutinib at UCSF.
  • Descriptive statistics and Kaplan-Meier methods were used for outcome assessment.
  • Patient data includes age, sex, race, comorbidities, and treatment history.
  • Adverse events were identified via clinical notes analysis using a language model.
  • Total of 175 patients included, median follow-up of 18 months.
  • ZANU patients had lower likelihood of starting next treatment than ACA (HR: 0.53).
  • Median overall survival was noted but not statistically significant between groups.
  • Charlson Comorbidity Index indicated worse outcomes with higher scores.
  • 97% of patients experienced at least one adverse event during treatment.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4cfhttps://doi.org/10.1182/blood-2025-4528
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices.2024 · 2 citations
  2. 2Real-world treatment and survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naive patients with chronic lymphocytic leukemia (CLL) in the United States.2026
  3. 3Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL).2026
  4. 4Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL).2024 · 2 citations
  5. 5A real-world comparison of treatment and survival outcomes with zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States.2026